164 related articles for article (PubMed ID: 15127940)
1. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.
Hoare SR; Sullivan SK; Pahuja A; Ling N; Crowe PD; Grigoriadis DE
Peptides; 2003 Dec; 24(12):1881-97. PubMed ID: 15127940
[TBL] [Abstract][Full Text] [Related]
2. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
3. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
4. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
Myers DA; Trinh JV; Myers TR
Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
[TBL] [Abstract][Full Text] [Related]
5. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
Oshida Y; Ikeda Y; Chaki S; Okuyama S
Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
[TBL] [Abstract][Full Text] [Related]
6. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
Primus RJ; Yevich E; Baltazar C; Gallager DW
Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists.
Hoare SR; Sullivan SK; Ling N; Crowe PD; Grigoriadis DE
Mol Pharmacol; 2003 Mar; 63(3):751-65. PubMed ID: 12606786
[TBL] [Abstract][Full Text] [Related]
8. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
9. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.
Dautzenberg FM; Huber G; Higelin J; Py-Lang G; Kilpatrick GJ
Neuropharmacology; 2000 Jun; 39(8):1368-76. PubMed ID: 10818253
[TBL] [Abstract][Full Text] [Related]
10. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.
Ardati A; Goetschy V; Gottowick J; Henriot S; Valdenaire O; Deuschle U; Kilpatrick GJ
Neuropharmacology; 1999 Mar; 38(3):441-8. PubMed ID: 10219982
[TBL] [Abstract][Full Text] [Related]
11. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
Gottowik J; Goetschy V; Henriot S; Kitas E; Fluhman B; Clerc RG; Moreau JL; Monsma FJ; Kilpatrick GJ
Neuropharmacology; 1997 Oct; 36(10):1439-46. PubMed ID: 9423932
[TBL] [Abstract][Full Text] [Related]
12. Evidence that corticotropin-releasing factor receptor type 1 couples to Gs- and Gi-proteins through different conformations of its J-domain.
Berger H; Heinrich N; Wietfeld D; Bienert M; Beyermann M
Br J Pharmacol; 2006 Dec; 149(7):942-7. PubMed ID: 17057757
[TBL] [Abstract][Full Text] [Related]
13. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
[TBL] [Abstract][Full Text] [Related]
14. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
15. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
Dautzenberg FM; Kilpatrick GJ; Wille S; Hauger RL
J Neurochem; 1999 Aug; 73(2):821-9. PubMed ID: 10428081
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells.
Wietfeld D; Heinrich N; Furkert J; Fechner K; Beyermann M; Bienert M; Berger H
J Biol Chem; 2004 Sep; 279(37):38386-94. PubMed ID: 15252011
[TBL] [Abstract][Full Text] [Related]
17. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.
Rominger DH; Rominger CM; Fitzgerald LW; Grzanna R; Largent BL; Zaczek R
J Pharmacol Exp Ther; 1998 Jul; 286(1):459-68. PubMed ID: 9655891
[TBL] [Abstract][Full Text] [Related]
18. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
[TBL] [Abstract][Full Text] [Related]
19. Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
Bonk I; Rühmann A
Eur J Biochem; 2002 Nov; 269(21):5288-94. PubMed ID: 12392562
[TBL] [Abstract][Full Text] [Related]
20. High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1.
Rühmann A; Bonk I; Köpke AK
Peptides; 1999 Nov; 20(11):1311-9. PubMed ID: 10612445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
